Amid high volumes of trading, shares in Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) have fallen almost a fifth in New York this morning, as the company revealed disappointing quarterly results.
The company made a net loss of $6 billion, equivalent to $5.94 per share following generally accepted accounting principles (GAAP), compared to a profit of $188 million in the same period last year.
The loss is mainly due to weak performance at the former generics arm of Allergan, a recent Teva acquisition, leading to a $6.1 billion impairment charge. When the ‘goodwill’ cost of an investment fails to materialize, it is regarded as good financial practice to book this as a write off, for the sake of transparency.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze